title: Dopamine D2 receptor control of pallidal fos expression: comparisons between intact and 6-hydroxydopamine-treated hemispheres.
abstract: Fos expression in the globus pallidus (GP) of rats was elicited by the D2 agonist quinpirole both ipsilateral and contralateral to a unilateral nigrostriatal 6-hydroxydopamine (6-OHDA) injection; however, the 6-OHDA-treated hemisphere was more sensitive to this effect. The quinpirole-induced GP Fos expression was antagonized in both hemispheres by the D2 antagonist eticlopride, but not by the D1 antagonist SCH 23390. In neurologically intact rats, the D1 agonist SKF 38393, which alone did not elicit pallidal Fos expression, augmented the quinpirole-induced Fos response. Thus, D1 agonists can synergize with D2 agonists in inducing GP c-fos; but the D2-stimulated induction does not depend on concurrent D1 agonism.
authors.affiliation: Department of Psychobiology, University of California at Irvine 92717-4550.
authors.forename: J F
authors.initials: JF
authors.lastname: Marshall
authors.forename: B N
authors.initials: BN
authors.lastname: Cole
authors.forename: G J
authors.initials: GJ
authors.lastname: LaHoste
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D015259:Dopamine Agents / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004873:Ergolines / Q000494:pharmacology*; D007839:Functional Laterality; D015870:Gene Expression / Q000187:drug effects*; D016762:Genes, fos; D005917:Globus Pallidus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D016627:Oxidopamine; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis / Q000096:biosynthesis*; D019257:Quinpirole; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D012457:Salicylamides / Q000494:pharmacology; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000502:physiology*
chemical_list: D001552:Benzazepines; D015259:Dopamine Agents; D065127:Dopamine D2 Receptor Antagonists; D004873:Ergolines; D016760:Proto-Oncogene Proteins c-fos; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine; C045989:eticlopride